Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA

被引：34

作者：

Brahe, Cecilie Heegaard ^{[1
,2
]}

Ornbjerg, Lykke Midtboll ^{[1
,2
]}

Jacobsson, Lennart ^{[3
]}

Nissen, Michael J. ^{[4
]}

Kristianslund, Eirik Klami ^{[5
]}

Mann, Herman ^{[6
,7
]}

Santos, Maria Jose ^{[8
,9
]}

Reino, Juan Gomez ^{[10
]}

Nordstrom, Dan ^{[11
,12
]}

Rotar, Ziga ^{[13
,14
]}

Gudbjornsson, Bjorn ^{[15
,16
]}

Onen, Fatos ^{[17
,18
]}

Codreanu, Catalin ^{[19
]}

Lindstrom, Ulf ^{[3
]}

Moller, Burkhard ^{[20
]}

Kvien, Tore K. ^{[5
]}

Pavelka, Karel ^{[6
,7
]}

Barcelos, Anabela ^{[21
,22
]}

Sanchez-Piedra, Carlos ^{[10
]}

Eklund, Kari K. ^{[23
]}

Tomsic, Matija ^{[13
,14
]}

Love, Thorvardur Jon ^{[16
,24
]}

Can, Gercek ^{[17
,18
]}

Ionescu, Ruxandra ^{[19
]}

Loft, Anne Gitte ^{[2
,25
]}

van der Horst-Bruinsma, I. E. ^{[26
,27
]}

Macfarlane, Gary J. ^{[28
]}

Iannone, Florenzo ^{[29
]}

Hyldstrup, Lise Hejl ^{[1
]}

Krogh, Niels Steen ^{[30
]}

Ostergaard, Mikkel ^{[1
,31
]}

Hetland, Merete Lund ^{[1
,31
]}

机构：

[1] Rigshosp, Ctr Head & Orthopaed, Ctr Rheumatol & Spine Dis, EuroSpA Coordinating Ctr,Copenhagen Ctr Arthrit R, Glostrup, Denmark

[2] Rigshosp, Ctr Rheumatol & Spine Dis, Ctr Head & Orthopaed, DANBIO Registry, Glostrup, Denmark

[3] Univ Gothenburg, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden

[4] Geneva Univ Hosp, Dept Rheumatol, Geneva, Switzerland

[5] Diakonhjemmet Hosp, Dept Rheumatol, Oslo, Norway

[6] Charles Univ Prague, Fac Med 1, Inst Rheumatol, Prague, Czech Republic

[7] Charles Univ Prague, Dept Rheumatol, Prague, Czech Republic

[8] Univ Lisbon, Fac Med, Reumapt Registry, Lisbon, Portugal

[9] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal

[10] Spanish Soc Rheumatol, Res Unit, Madrid, Spain

[11] Univ Helsinki, ROB FIN Registry, Helsinki, Finland

[12] Helsinki Univ Hosp, Helsinki, Finland

[13] Biorxsi, Ljubljana, Slovenia

[14] Univ Med Ctr Ljubljana, Dept Rheumatol, Ljubljana, Slovenia

[15] Univ Hosp, Ctr Rheumatol Res, Reykjavik, Iceland

[16] Univ Iceland, Fac Med, Reykjavik, Iceland

[17] Dokuz Eylul Univ, TURKBIO Registry, Sch Med, Izmir, Turkey

[18] Dokuz Eylul Univ, Div Rheumatol, Sch Med, Izmir, Turkey

[19] Univ Med & Pharm, Ctr Rheumat Dis, Bucharest, Romania

[20] Inselspital Bern, Leitender Arzt Univ Klin Rheumatol Immunol & Alle, Bern, Switzerland

[21] Univ Aveiro, Ctr Hosp Baixo Vouga, Rheumapt Registry, Rheumatol Dept, Aveiro, Portugal

[22] Univ Aveiro, Inst Biomed, Ibimed, Aveiro, Portugal

[23] Helsinki Univ Hosp, Inflammat Ctr, Dept Rheumatol, Helsinki, Finland

[24] Landspitali Univ Hosp, Reykjavik, Iceland

[25] Aarhus Univ Hosp, Dept Rheumatol, Aarhus, Denmark

[26] Acad Med Ctr, Amsterdam Rheumatol & Immunol Ctr ARC, Amsterdam, Netherlands

[27] Vrije Univ Amsterdam, Med Ctr Amsterdam, Dept Rheumatol, Amsterdam UMC, Amsterdam, Netherlands

[28] Univ Aberdeen, Sch Med Med Sci & Nutr, Epidemiol Grp, Aberdeen, Scotland

[29] Univ Bari, Rheumatol Unit DETO, GISEA Registry, Bari, Italy

[30] Zitelabs Aps, Copenhagen, Denmark

[31] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark

来源：

RHEUMATOLOGY | 2020年 / 59卷 / 07期

关键词：

psoriatic arthritis; spondyloarthritis; TNFi; effectiveness; drug survival; response; epidemiology; register; DAS28; DAPSA28; NECROSIS-FACTOR INHIBITORS; MODIFYING ANTIRHEUMATIC DRUGS; PSORIATIC-ARTHRITIS; RHEUMATOID-ARTHRITIS; PREDICTORS THEREOF; CLINICAL-PRACTICE; INFLIXIMAB; SURVIVAL; THERAPY; COMEDICATION;

D O I：

10.1093/rheumatology/kez427

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naive patients with PsA. Methods. Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) <2.6; 28 joint Disease Activity index for Psoriatic Arthritis 4] and ACR criteria for 20% improvement (ACR20)/ACR50/ACR70 were calculated, including LUNDEX adjustment. Results. Overall, 14 261 patients with PsA initiated a first TNFi. Considerable heterogeneity of baseline characteristics between registries was observed. The median 12-month retention rate (95% CI) was 77% (76, 78%), ranging from 68 to 90% across registries. Overall, DAS28/28 joint Disease Activity index for Psoriatic Arthritis remission rates at 6 months were 56%/27% (LUNDEX: 45%/22%). Six-month ACR20/50/70 responses were 53%/38%/22%, respectively. In patients initiating a first TNFi after 2009 with registered fulfilment of ClASsification for Psoriatic ARthritis (CASPAR) criteria (n = 1980) or registered one or more swollen joint at baseline (n = 5803), the retention rates and response rates were similar to those found overall. Conclusion. Approximately half of >14 000 patients with PsA who initiated first TNFi treatment in routine care were in DAS28 remission after 6 months, and three-quarters were still on the drug after 1 year. Considerable heterogeneity in baseline characteristics and outcomes across registries was observed. The feasibility of creating a large European database of PsA patients treated in routine care was demonstrated, offering unique opportunities for research with real-world data.

引用

页码：1640 / 1650

页数：11

共 36 条

[1] Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice [J].